

PRESENTED BY:



SPONSORED BY:



CONTINUING MEDICAL EDUCATION

**Pediatric Hematology/Oncology Tumor Board - 5/18/2023 –
55647-53867**

Date: May 18, 2023

Time: 12:00 PM-1:00 PM

UH Cleveland Medical Center

Duncan Stearns, MD; Rachel Egler, MD
Case Western Reserve School of Medicine, Rainbow Babies and Children's Hospital

Educational Objectives

At the conclusion of this activity, the participant should be better able to:

- 1 Identify and apply the principles of quality and safety to their practice
- 2 Review appropriate therapeutic modalities
- 3 Discuss chemotherapy response
- 4 Evaluate survival and prognostic factors

Accreditation and Credit Designation Statements

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures:

All relevant financial relationships have been mitigated. This activity's planners and speaker(s) have made the following disclosures:

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Duncan Stearns, MD	Co-Director, Faculty	Advisor-AstraZeneca (Relationship has ended) - 07/05/2022
Rachel Egler, MD	Course Director, Faculty	Nothing to disclose - 06/10/2022
Melissa Makii, PharmD	Other Planning Committee Member	Paid consultant-Lexicomp Paid consultant-Takeda Pharmaceuticals, Inc. - 06/30/2022
Kristen Nagle, CNP, MSN	Other Planning Committee Member	Nothing to disclose - 06/30/2022
Breanne Roche, DNP, RN, CPNP	Other Planning Committee Member	Paid consultant-BTG Specialty Pharmaceuticals Advisor-AstraZeneca (Relationship has ended) Advisor-Alexion - 06/30/2022